Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer

BACKGROUND: Dual-targeted therapy is the standard treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and effective biomarkers to predict the response to neoadjuvant trastuzumab and pertuzumab treatment need further investigation. Here, we developed a predictive mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Yi, Ding, Jiahan, Ma, Dachang, Chen, Sheng, Li, Xun, Yu, Keda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161548/
https://www.ncbi.nlm.nih.gov/pubmed/35663978
http://dx.doi.org/10.3389/fimmu.2022.877825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161548/
https://www.ncbi.nlm.nih.gov/pubmed/35663978
http://dx.doi.org/10.3389/fimmu.2022.877825

Ejemplares similares